Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. develops intranasal foralumab, a fully human anti-CD3 monoclonal antibody, as a clinical-stage biotechnology company focused on neuroinflammatory and neurodegenerative diseases. News for TLSA centers on clinical and preclinical data for intranasal anti-CD3 therapy, including non-active secondary progressive multiple sclerosis, Multiple System Atrophy, Alzheimer’s disease, ALS, Long COVID-associated neuroinflammation, and age-related cognitive decline.
Company updates also cover biomarker work involving CSF proteomics, TSPO-PET and microglial activation, peer-reviewed publications, scientific conference presentations, expanded-access observations, and financing actions such as registered direct offerings of ordinary shares and warrants.
Tiziana Life Sciences announced that its CEO and CSO, Dr. Kunwar Shailubhai, will host a fireside chat on January 21, 2021, at 3 PM ET / 8 PM GMT. The discussion will provide updates on the company's ongoing developments, particularly in oncology and inflammation. Tiziana is advancing therapeutics such as Foralumab, a fully human anti-CD3 monoclonal antibody, and its IL6R monoclonal antibody for treating COVID-19. Interested parties can join the webcast through a provided link.
Tiziana Life Sciences has announced its transition from AIM to the Main Market of the London Stock Exchange, effective January 21, 2021. Following the last trading day on AIM on January 20, the Company’s Ordinary Shares will be admitted to the Official List and commence trading on the Main Market. Tiziana focuses on developing innovative treatments for oncology, inflammation, and infectious diseases, with ongoing Phase 2 studies for its uniquely human anti-CD3 monoclonal antibody, Foralumab, targeting conditions such as Crohn's Disease and multiple sclerosis.
Tiziana Life Sciences plc (NASDAQ: TLSA) announced the appointment of Dr. Neil Graham as Chief Medical Officer. Dr. Graham has extensive experience in medicines development, having previously held roles at Regeneron and Vertex. He played a key role in the launch of blockbuster drugs like Dupixent. Tiziana's unique monoclonal antibody platform for autoimmune diseases could significantly impact the treatment landscape. The company is advancing clinical studies for Foralumab, an innovative monoclonal antibody addressing various autoimmune conditions.
Tiziana Life Sciences plc (NASDAQ: TLSA) has announced its participation in the J.P. Morgan 39th Annual Healthcare Conference 2021. CEO Dr. Kunwar Shailubhai expressed excitement about presenting significant advancements, including topline data from a COVID-19 trial expected this month and anticipated launches of multiple Phase 2 trials in 2021. The company is exploring Foralumab, a fully human anti-CD3 monoclonal antibody, for various autoimmune diseases and aims to address IL6-induced inflammation in COVID-19 patients. For more details, visit Tiziana's website.
Tiziana Life Sciences (NASDAQ: TLSA) announced its participation in Biotech Showcase 2021, providing on-demand presentations for attendees. Dr. Kunwar Shailubhai, CEO, stated that topline data from a COVID-19 trial is expected this month, with several Phase 2 trial launches planned for 2021. With the potential application of Foralumab in various autoimmune diseases, the company aims to achieve significant milestones impacting its valuation. Biotech Showcase serves as a networking platform for life science professionals and investors, promoting innovations in drug discovery.
Tiziana Life Sciences (Nasdaq: TLSA) has completed a clinical study in Brazil on nasally administered Foralumab for COVID-19 patients. The trial showed positive anecdotal feedback from patients, highlighting rapid improvement in smell sensation, a common COVID-19 symptom. The study involved 39 patients with moderate to severe COVID-19, assessing safety and efficacy against the disease. Topline data is expected in January 2021, with implications for treating coronaviruses as well as potential applications in other diseases. This novel approach aims to enhance the immune response against COVID-19 variants.
Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) announces its admission of ordinary shares to the Official List of the FCA and the Main Market of the London Stock Exchange. The prospectus for this listing was approved on December 18, 2020. Key dates include the last day of trading on AIM on January 20, 2021, with delisting and trading on the Main Market commencing on January 21, 2021, at 8:00 am. Tiziana is focused on innovative therapeutics for oncology and other diseases, including advancing clinical studies for its unique fully human anti-CD3 monoclonal antibody for various conditions.
Tiziana Life Sciences (Nasdaq: TLSA) has announced its application for a standard listing on the Official List of the FCA and trading admission on the London Stock Exchange's Main Market. The company will cancel AIM trading, effective January 21, 2021, and will not issue new shares during this transition. The prospectus is expected to be published on December 18, 2020. Tiziana focuses on innovative therapeutics for oncology, inflammation, and infectious diseases, with phase 2 studies planned for its drug, foralumab.
Tiziana Life Sciences plc (NASDAQ: TLSA), a biotechnology company specializing in therapeutics for oncology and infectious diseases, announced a conference call led by CEO and CSO Dr. Kunwar Shailubhai on December 2, 2020, at 4:15 p.m. ET. The call will cover the company's transition from AIM to the London Stock Exchange's Standard Segment, updates on ongoing clinical trials, and recent developments. Individuals unable to attend can access a replay until December 16, 2020. The company is known for its innovative treatments, including Milciclib and Foralumab, addressing various autoimmune diseases.
Tiziana Life Sciences has disclosed that Gabriele Cerrone, Executive Chairman, acquired 45,000 ordinary shares at 84p each on November 18, 2020. This purchase increased Cerrone's shareholding from 34.029% to 34.052%, just above the 1% threshold under the UK Takeover Code. The acquisition reflects Cerrone's continued confidence in the company's prospects within the biotechnology sector, which focuses on oncology and infectious diseases.